Celldex Therapeutics reports Q1 2026 results on May 11 with short sellers maintaining a meaningful position — but the borrow market tells a story of fading conviction rather than escalating pressure.
Short interest is a genuine story here at 12.5% of the free float, making CLDX one of the more heavily shorted names in the biotech space. Yet the direction has changed sharply. Short positions fell roughly 9% over the past month, from around 9.1 million shares in late March to 8.3 million now — a notable retreat. Borrowing costs have followed: cost to borrow has dropped 20% over the same period, now running at just 0.40%, well below the 0.70% level seen in early April. Lending availability remains ample, and with a 5.7% lending utilization rate far below the 52-week peak of 16.1%, there's plenty of capacity for new shorts to enter — but recent data suggests they haven't been doing so.
Options positioning adds a layer of caution to that picture. Put/call ratio has shifted more defensively into the print, running at 1.24 against a 20-day average of 1.03 — about one standard deviation above the recent norm. That's not extreme by historical standards; the 52-week high on the PCR reached 3.58, so current positioning is elevated but far from panicked. Combined with a 3.1% price drop on May 7, but a 6.2% gain over the past month and a 25% gain year-to-date, the stock has had a strong run and the options market reflects some hedging of that.
The analyst community is divided in a way that captures the binary nature of the barzolvolimab programme. Barclays made the most consequential recent move, flipping from Underweight to Overweight on April 20 and nearly doubling its price target from $24 to $45 — a sharp reversal from a firm that had been bearish on the name for months. Goldman Sachs, meanwhile, raised its target only modestly to $34 while staying Neutral, reflecting scepticism about the valuation. Bulls point to impressive Phase II durability data in chronic spontaneous urticaria and an upcoming 44-week readout from the CIndU programme as confirmation of barzolvolimab's potential. Bears flag the binary trial risk: any clinical stumble in Phase III could unwind the stock's recent momentum rapidly, and CLDX burns roughly $286 million in operating cash annually with minimal revenue. The consensus sits at "buy" with a mean target of $57 — implying 71% upside from current levels — though Goldman's $34 target (barely above spot) illustrates how wide the range of outcomes is.
Historical earnings reactions have been consistently positive. The past three prints produced single-day moves of +23%, +8%, and +6% respectively, and five-day moves ranging from +14% to +30%. That pattern reflects the stock's sensitivity to trial data updates bundled into earnings releases. The May 11 print is therefore less a test of financial performance — there's minimal revenue to speak of — and more a referendum on whether clinical progress justifies the stock's re-rating since the start of the year.
See the live data behind this article on ORTEX.
Open CLDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
